Results 121 to 130 of about 20,876 (147)

Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis. [PDF]

Clinicoecon Outcomes Res
Thompson JA, Gupta A, Catini J, Laires PA.   +3 more
europepmc   +1 more source

Recent developments in systemic light-chain amyloidosis prognosis and treatment. [PDF]

Future Cardiol
Ioannou A.
europepmc   +1 more source

Diagnostic pathways, cardiac manifestations, and outcomes in light chain amyloidosis: a plain language summary. [PDF]

Future Cardiol
Lyons G, Thompson J, Lousada I, Catini J, Manwani R, Maurer MS.   +5 more
europepmc   +1 more source

Novel Cut-Off Values of Precordial Voltage Indexes for Light Chain Amyloidosis Cardiomyopathy in a Chinese Population. [PDF]

J Cardiovasc Dev Dis
Pan R, Zhuang S, Wang Z, Ren X, Tian Z, Zhang S.   +5 more
europepmc   +1 more source

Cryo-EM structure of renal AL amyloid fibrils from a patient with λ1 light chain amyloidosis. [PDF]

Nat Commun
Yu C, Ma Y, Li H, Liu K, Huang H, Zhao K.   +5 more
europepmc   +1 more source

Hepatic-Predominant Immunoglobulin G Lambda Light Chain Amyloidosis Associated With Multiple Myeloma: A Report of an Exceptionally Rare Case. [PDF]

Cureus
Jesus G, Soares I, Silva AS, Baptista M, Gonçalves Ribeiro A.   +4 more
europepmc   +1 more source

Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis. [PDF]

Ann Med
Li X, Chen M, Liu J, Gu J, Huang B, Kuang L, Li J.   +6 more
europepmc   +1 more source

BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis. [PDF]

Curr Oncol
Lewis E, Jimenez-Zepeda VH.
europepmc   +1 more source

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.

Blood
Vianna P, Chakraborty R, Hossain S, Bhutani D, Miller S, Rossi A, Cuddy SAM, Falk RH, Lentzsch S, Laubach JP, Bianchi G.   +10 more
europepmc   +1 more source